Teva Pharmaceuticals Wins $46.1M Military Contract for Adenovirus Vaccines

Teva Pharmaceuticals USA Inc., Parsippany, New Jersey, has been awarded a maximum $46,087,497 modification (P00009) exercising the third one-year option period of a five-year base contract (SPE2DP-20-D-0002) with five one-year option periods for adenovirus type 4 and type 7 vaccines. This was a sole-source acquisition using justification 10 U.S. Code 3204 (a)(1), as stated in Federal Acquisition Regulation 6.302-1. This is a firm-fixed-price, indefinite delivery/indefinite-quantity contract. The ordering period end date is Dec. 31, 2027. Using customers are Army, Navy, Air Force, Marine Corps and Coast Guard. Type of appropriation is fiscal 2026 through 2027 defense working capital funds. The contracting activity is Defense Logistics Agency Troop Support, Philadelphia, Pennsylvania.